The PDUFA date in April 2027 and the CREAATE topline data in 1Q2027 are the next major catalysts. Monitor FDA advisory committee meeting announcements and any updates on the MAA review in Europe. The cash position appears sufficient to fund operations through these milestones without near-term dilution.
Drug in focus
PHVS drug pipeline →deucrictibant
◆ Mixed Named in this press release- Impact
- Phase
- Filed/PDUFA (IR capsule); Phase 3 (XR tablet)
- Time to market
- IR capsule could be approved by April 23, 2027 PDUFA date. XR tablet for prophylaxis would follow later, likely 2028+ if CHAPTER-3 is positive.
- Next catalyst
- None dated
What to watchTwo binary catalysts in the next ~9 months: CHAPTER-3 topline (Q3 2026) and the PDUFA decision on the IR capsule (April 23, 2027). The bigger swing factor near-term is CHAPTER-3, a positive readout would validate the larger prophylactic market opportunity, while a miss would severely dent the thesis given that sebetralstat (KalVista) already beat deucrictibant to market as the first oral on-demand HAE therapy.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $33.83entry
- T+1 · 4d ago −1.39%α −1.03% · $33.36
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Pharvaris reported Q3 2026 results with a net loss of €47.4M ($0.67 per share), slightly wider than the €37.1M loss in Q3 2025. The key stock-moving catalyst is the FDA PDUFA date of April 23, 2027 for deucrictibant IR as an on-demand HAE treatment, and the upcoming topline data from the Phase 3 CREAATE study in 1Q2027. The company has €283M in cash to fund operations through these milestones.
Key Financial Metrics
Key Facts
- FDA PDUFA action date for deucrictibant IR NDA is April 23, 2027
- Topline data from Phase 3 CREAATE study (AAE-C1INH prophylaxis) expected in 1Q2027
- CHAPTER-3 Phase 3 study met primary endpoint: 83% reduction in monthly HAE attack rate (p<0.0001)
- Cash and cash equivalents of €283M as of September 30, 2026
- Q3 2026 net loss of €47.4M ($0.67 per share) vs €37.1M ($0.60) in Q3 2025
- NDA filing for deucrictibant XR prophylaxis expected in 1H2027
Financial Impact
Q3 2026 net loss of €47.4M; cash burn of ~€9M from €292M at year-end 2025 to €283M at Q3 2026
Risk Factors
- FDA may issue a Complete Response Letter or require additional data before approval
- CREAATE study results may not replicate the efficacy seen in CHAPTER-3
- Competition from existing HAE therapies (Takhzyro, Haegarda, Orladeyo) may limit commercial uptake
- Foreign exchange risk as the company reports in EUR but trades in USD
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3401374 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Viewing Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers